InsiderClue
Stocks · Health care · Pharmaceutical Preparations

GALECTIN THERAPEUTICS INC

GALT Clue Score21
United States Fiscal year ends December CIK 0001133416 Results filed 14 Aug 2026
Add to watchlist

What the insiders did Net selling

Individual transactions

43
Insider
Date
Role
Action
Shares
Price
Amount
Khurram Jamil
14 Jul 2026
Chief Medical Officer
Sold after exercise
16,250
$5.13
$83.28K
Khurram Jamil
29 Jun 2026
Chief Medical Officer
Sold after exercise
47,467
$5.04
$239.23K
Harold H. Shlevin
29 Jun 2026
Director
Sold after exercise
22,268
$5.04
$112.23K
Khurram Jamil
26 Jun 2026
Chief Medical Officer
Sold after exercise
2,533
$5.00
$12.67K
Khurram Jamil
26 Jun 2026
Chief Medical Officer
Sold after exercise
2,037
$5.00
$10.19K
Harold H. Shlevin
26 Jun 2026
Director
Sold after exercise
7,732
$5.00
$38.66K
Khurram Jamil
23 Jun 2026
Chief Medical Officer
Sold after exercise
7,557
$3.14
$23.73K
Khurram Jamil
26 May 2026
Chief Medical Officer
Sold after exercise
568
$3.10
$1.76K
Khurram Jamil
2 Jan 2026
Chief Medical Officer
Sold after exercise
13,055
$4.20
$54.79K
Jack W Callicutt
2 Jan 2026
Chief Financial Officer
Sold after exercise
13,914
$4.20
$58.39K
Joel Lewis
2 Jan 2026
President and CEO
Sold after exercise
18,571
$4.20
$77.94K
Khurram Jamil
31 Dec 2025
Chief Medical Officer
Sold after exercise
8,125
$4.07
$33.09K
Harold H. Shlevin
17 Dec 2025
Director
Sold after exercise
4,706
$7.04
$33.12K
Harold H. Shlevin
17 Dec 2025
Director
Sold after exercise
19,793
$7.04
$139.30K
Khurram Jamil
17 Dec 2025
Chief Medical Officer
Sold after exercise
8,500
$7.04
$59.84K
Khurram Jamil
17 Dec 2025
Chief Medical Officer
Sold after exercise
6,463
$7.04
$45.50K
Khurram Jamil
17 Dec 2025
Chief Medical Officer
Sold after exercise
4,479
$7.04
$31.53K
Joel Lewis
17 Dec 2025
President and CEO
Sold after exercise
7,829
$7.06
$55.24K
Harold H. Shlevin
15 Dec 2025
Director
Sold after exercise
8,417
$6.30
$53.03K
Harold H. Shlevin
12 Dec 2025
Director
Sold after exercise
19,793
$6.27
$124.18K
Harold H. Shlevin
9 Dec 2025
Director
Sold after exercise
16,790
$6.27
$105.21K
Harold H. Shlevin
8 Dec 2025
Director
Sold after exercise
20,000
$6.00
$120.04K
Harold H. Shlevin
8 Dec 2025
Director
Sold after exercise
35,000
$6.02
$210.67K
Harold H. Shlevin
8 Dec 2025
Director
Sold after exercise
25,000
$5.95
$148.65K
Harold H. Shlevin
8 Dec 2025
Director
Sold after exercise
20,000
$5.96
$119.24K
Harold H. Shlevin
8 Dec 2025
Director
Sold after exercise
20,000
$5.96
$119.24K
Harold H. Shlevin
8 Dec 2025
Director
Sold after exercise
35,000
$5.95
$208.25K
Harold H. Shlevin
8 Dec 2025
Director
Sold after exercise
4,000
$6.01
$24.02K
Jack W Callicutt
18 Nov 2025
Chief Financial Officer
Sold after exercise
18,210
$6.22
$113.32K
Jack W Callicutt
18 Nov 2025
Chief Financial Officer
Sold after exercise
28,100
$6.22
$174.87K
Joel Lewis
18 Nov 2025
President and CEO
Sold after exercise
6,783
$6.15
$41.72K
Jack W Callicutt
17 Nov 2025
Chief Financial Officer
Sold after exercise
2,323
$6.03
$14.01K
Jack W Callicutt
17 Nov 2025
Chief Financial Officer
Sold after exercise
19,701
$6.03
$118.83K
Jack W Callicutt
17 Nov 2025
Chief Financial Officer
Sold after exercise
9,586
$6.03
$57.82K
Joel Lewis
17 Nov 2025
President and CEO
Sold after exercise
15,680
$6.04
$94.64K
Khurram Jamil
13 Nov 2025
Chief Medical Officer
Sold after exercise
16,250
$5.47
$88.89K
Khurram Jamil
13 Nov 2025
Chief Medical Officer
Sold after exercise
41,500
$5.47
$227.01K
Khurram Jamil
13 Nov 2025
Chief Medical Officer
Sold after exercise
41,500
$5.47
$227.01K
Khurram Jamil
13 Nov 2025
Chief Medical Officer
Sold after exercise
21,867
$5.47
$119.61K
Jack W Callicutt
10 Nov 2025
Chief Financial Officer
Sold after exercise
1,736
$6.03
$10.47K
Jack W Callicutt
10 Nov 2025
Chief Financial Officer
Sold after exercise
1,675
$6.03
$10.09K
Jack W Callicutt
10 Nov 2025
Chief Financial Officer
Sold after exercise
1,880
$6.02
$11.32K
Joel Lewis
10 Nov 2025
President and CEO
Sold after exercise
1,867
$6.03
$11.25K
Show all 59 transactions →

What was left out

Form 4 filings counted 43
Amendments (4/A) skipped 4
Filings about a different issuer 0
Unreadable filings 0
Joint filings 3
Sales on a Rule 10b5-1 plan 6
Sales straight out of an exercise 43
Sales at will 4
Transactions with no price 0
Shares from compensation/vesting 35,181,445
History held since 9 Feb 2007